| Treatment outcome (No, %) [95 CI] | ||
---|---|---|---|
 | Rural area (n = 62) | Urban area (n = 55) | Total (n = 117) |
ETF | 0 (0%) [0–6%] | 0 (0%) [0–6%] | 0 (0%) [0–3%] |
LCF | Â | Â | Â |
- Recrudescence | 0 (0%) [0–6%] | 5 (9%) [3–20%] | 5 (4%) [1–10%] |
- New infection | 0 (0%) [0–6%] | 1 (2%) [0–10%] | 1 (1%) [0–5%] |
- No genotyping results | 1 (2%) [0–9%] | 0 (0%) [0–6%] | 1 (1%) [0–5%] |
LPF | Â | Â | Â |
- Recrudescence | 1 (2%) [0–9%] | 1 (2%) [0–10%] | 2 (2%) [0–6%] |
- New infection | 2 (3%) [0–11%] | 2 (4%) [0–13%] | 4 (3%) [1–9%] |
- No genotyping results | 1 (2%) [0–9%] | 0 (0%) [0–6%] | 1 (1%) [0–5%] |
ACPR | 57 (92%) [82–97%] | 46 (84%) [71–92%] | 103 (88%) [81–93%] |
ACPR (pcr-corrected) | 58 (94%) [84–98%] | 50 (91%) [80–97%] | 108 (92%) [86–96%] |